Krsnaa Diagnostics Board Approves Q1 FY27 Results, Declares Dividend, Issues Warrants
Krsnaa Diagnostics approved Q1 FY27 unaudited results and declared a final dividend of ₹2.00 per share. The company will issue 16,21,000 warrants to promoters at a price determined by floor price or ₹565. The 16th AGM is scheduled for September 28, 2026.
The approval of financial results and dividend declaration are routine. The issuance of warrants, while positive, has an undetermined price and a future exercise period, limiting its immediate high impact. The AGM announcement is also a standard corporate event.
The company announced positive financial results, declared a dividend, and approved the issuance of warrants to promoters, which can be seen as a positive development for future funding and promoter confidence.
Krsnaa Diagnostics Limited announced the outcome of its Board Meeting held on August 13, 2026. The Board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the limited review reports. They also approved the Director's report for the financial year 2025-26 and the notice for the 16th Annual General Meeting (AGM) scheduled for September 28, 2026, at 11:00 AM IST, to be held in physical mode.
The Board declared a final dividend of ₹2.00 per share for FY 2024-25. The record date for dividend payment is September 18, 2026, with book closure from September 19, 2026, to September 28, 2026.
Furthermore, the company approved the issuance of 16,21,000 share warrants to Mr. Rajendra Mutha and Krsna Diagnostics (Mumbai) Private Limited (Promoter and Promoter Group). The issue price will be determined in the future, at the higher of the floor price or ₹565/-. Each warrant is convertible into one equity share of face value ₹5/- and can be exercised within 18 months from the allotment date.
The Board Meeting commenced at 1:30 PM IST and concluded at 9:00 PM IST. The company also addressed tax assessment orders for various assessment years, with management confident of no material impact on the financial position.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.